Best Practice & Research Clinical Rheumatology
Volume 23, Issue 2 , Pages 291-303 , April 2009

How to perform a critical analysis of a randomised controlled trial

  • Candice Estellat (Assistant Professor of Epidemiology)

      Affiliations

    • INSERM U738, Paris, France
    • Université Paris 7, UFR de Médecine, Paris, France
    • AP-HP, Hôpital Bichat, Département d'Epidémiologie, Biostatistique et Recherche Clinique, Paris, France
    • Corresponding Author InformationCorresponding author. INSERM U738, Department d'Epidémiologie, de Biostatistique et de Recherche Clinique, Groupe Hospitalier Bichat – Claude Bernard, 46 rue Henri Huchard, 75877 Paris Cedex 18, France. Tel.: +33 1 40 25 79 44; Fax: +33 1 40 25 67 73.
    • ,
  • David J. Torgerson (Professor, Director York trials unit)

      Affiliations

    • Department of Health Sciences, University of York, York, UK
    • ,
  • Philippe Ravaud (Professor of Epidemiology)

      Affiliations

    • INSERM U738, Paris, France
    • Université Paris 7, UFR de Médecine, Paris, France
    • AP-HP, Hôpital Bichat, Département d'Epidémiologie, Biostatistique et Recherche Clinique, Paris, France

References 

  1. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. J Am Med Assoc. 1993;270:2598–2601
  2. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. J Am Med Assoc. 1994;271:59–63
  3. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc. 2001;285:1987–1991
  4. Greenhalgh T. Assessing the methodological quality of published papers. BMJ. 1997;315:305–308
  5. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007, Issue 2. Art No.:MR000012. doi:10.1002/14651858.MR000012.pub2.
  6. Montori VM, Bhandari M, Devereaux PJ, et al. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol. 2002;55:787–790
  7. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336:601–605
  8. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359:696–700
  9. Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med. 2006;3:e425
  10. Boutron I, Guittet L, Estellat C, et al. Reporting Methods of Blinding in Randomized Trials Assessing Nonpharmacological Treatments. PLoS Med. 2007;4:e61
  11. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670–674
  12. Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust. 2003;179:438–440
  13. Bergholdt K, Fabricius RN, Bendix T. Better backs by better beds?. Spine. 2008;33:703–708
  14. Baron G, Boutron I, Giraudeau B, et al. Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. Arthritis Rheum. 2005;52:1858–1865
  15. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT): a randomized trial. J Am Med Assoc. 2006;296:2441–2450
  16. Kyriakidi M, Ioannidis JP. Design and quality considerations for randomized controlled trials in systemic sclerosis. Arthritis Rheum. 2002;47:73–81
  17. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med. 1996;125:605–613
  18. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802–809
  19. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. J Am Med Assoc. 2004;291:2457–2465
  20. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–186
  21. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452–454
  22. Osiri M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis. 2003;62:316–321
  23. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733
  24. Keen HI, Pile K, Hill CL. The prevalence of underpowered randomized clinical trials in rheumatology. J Rheumatol. 2005;32:2083–2088
  25. Guyatt GH, Mills EJ, Elbourne D. In the era of systematic reviews, does the size of an individual trial still matter. PLoS Med. 2008;5:e4
  26. Altman DG, Bland JM. Statistics notes. Units of analysis. BMJ. 1997;314:1874
  27. Bolton S. Independence and statistical inference in clinical trial designs: a tutorial review. J Clin Pharmacol. 1998;38:408–412
  28. Rothwell PM. External validity of randomised controlled trials: ‘to whom do the results of this trial apply?. Lancet. 2005;365:82–93
  29. Farahani P, Levine M, Gaebel K, et al. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Can J Clin Pharmacol. 2005;12:e254–e263
  30. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788
  31. Tugwell P, Judd MG, Fries JF, et al. Powering our way to the elusive side effect: a composite outcome ‘basket’ of predefined designated endpoints in each organ system should be included in all controlled trials. J Clin Epidemiol. 2005;58:785–790
  32. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154:157–163

PII: S1521-6942(09)00027-8

doi: 10.1016/j.berh.2009.03.003

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 2 , Pages 291-303 , April 2009

Article Tools

* Image Usage & Resolution